Phathom Pharmaceuticals Inc - Asset Resilience Ratio

Latest as of March 2019: 2.07%

Phathom Pharmaceuticals Inc (PHAT) has an Asset Resilience Ratio of 2.07% as of March 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check PHAT strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

$1.76 Million
Cash + Short-term Investments

Total Assets

$84.88 Million
All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (None–None)

This chart shows how Phathom Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See how leveraged is Phathom Pharmaceuticals Inc's balance sheet to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Phathom Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Phathom Pharmaceuticals Inc.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $1.76 Million 2.07%
Total Liquid Assets $1.76 Million 2.07%

Asset Resilience Insights

  • Limited Liquidity: Phathom Pharmaceuticals Inc maintains only 2.07% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Phathom Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio

Compare Phathom Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
Biotechnology -55.36%
Krystal Biotech Inc
NASDAQ:KRYS
Biotechnology 23.06%
Verona Pharma PLC ADR
NASDAQ:VRNA
Biotechnology 0.00%
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
Biotechnology 33.37%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
Hebei Changshan Biochem Pharma
SHE:300255
Biotechnology -0.03%
BB Biotech AG
SW:BION
Biotechnology 0.05%

Annual Asset Resilience Ratio for Phathom Pharmaceuticals Inc (None–None)

The table below shows the annual Asset Resilience Ratio data for Phathom Pharmaceuticals Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
No yearly data available.
pp = percentage points

About Phathom Pharmaceuticals Inc

NASDAQ:PHAT USA Biotechnology
Market Cap
$858.15 Million
Market Cap Rank
#9744 Global
#2612 in USA
Share Price
$11.00
Change (1 day)
+5.47%
52-Week Range
$7.83 - $18.08
All Time High
$54.60
About

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical t… Read more